Sign In
Buy NVO
$48.03
+0.385 (+0.81%)
At Close: Jun 26, 2026
NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
06:49pm, Thursday, 13'th Mar 2025
NEW YORK , March 13, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and Decem
Shareholders that Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky about Pending Class Action - NVO
04:00pm, Thursday, 13'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws,
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
03:55pm, Thursday, 13'th Mar 2025
AbbVie Inc. entered the obesity market by in-licensing GUBamy, a long-acting amylin analog, a modest but important first step to challenge Eli Lilly and Novo Nordisk. AbbVie's will pay $350 million up
NVO Investors with Losses Encouraged to Contact the Firm Before Mar. 25th Deadline NVO Investors with Losses Encouraged to Contact the Firm Before Mar. 25th Deadline
Investors can contact the law firm at no cost to learn more about recovering their losses
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
02:25pm, Thursday, 13'th Mar 2025
With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the market.
NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Shareholders that Lost Money on Novo Nordisk A/S(NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
10:45am, Thursday, 13'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws,
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
10:31am, Thursday, 13'th Mar 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options If you purchased or acq
Class Action Filed Against Novo Nordisk A/S (NVO) - March 25, 2025 Deadline to Join - Contact Levi & Korsinsky
10:30am, Thursday, 13'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws,
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordi
NVO LAWSUIT ALERT: Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline
10:00am, Thursday, 13'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws,
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO
09:45am, Thursday, 13'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NASDAQ:NVO). Such investors are
Class Action Filed Against Novo Nordisk A/S (NVO) - March 25, 2025 Deadline to Join - Contact Levi & Korsinsky
09:30am, Thursday, 13'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws,
Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
09:10am, Thursday, 13'th Mar 2025
SAN FRANCISCO, CA / ACCESS Newswire / March 13, 2025 / National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Novo Nordisk A/S. ("Novo" or the "Company") (NYSE:NV
